Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated)
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) is a detoxified form of the pertussis toxin used as an active component in acellular pertussis vaccines. The toxin is chemically inactivated using formaldehyde and glutaraldehyde to eliminate toxicity while preserving immunogenicity. This antigen stimulates the immune system to produce antibodies against *Bordetella pertussis*, providing protection against whooping cough. It is typically administered as part of combination vaccines with diphtheria and tetanus toxoids and sometimes other antigens. The primary indication is prophylaxis of pertussis infection[4][3][1].
- Brand names
- AdacelBoostrixInfanrixKinrixPediarixPentacelQuadracel
- Other names
- Bordetella pertussis toxoid vaccine, inactivated
02
Targets
MHC II (Major histocompatibility complex class II receptor)T-cell receptor specific for pertussis-toxoid peptide–MHC II complexB-cell receptor specific for pertussis toxin
Beyond the preview
Go deeper on Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated).